RECQL4, mutated in the Rothmund–Thomson and RAPADILINO syndromes, interacts with ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway
Abstract
The Rothmund–Thomson syndrome (growth retardation, skin and bone defects, predisposition to cancer) and the RAPADILINO syndrome are caused by mutations in the RECQL4 gene. The 133 kDa RECQL4 is a putative DNA helicase, a member of the family that includes the BLM and WRN helicases. The latter are mutated, respectively, in the Bloom and Werner syndromes, whose manifestations include predisposition to cancer. Using antibodies to human RECQL4, we found that the bulk of RECQL4 was present in a cytoplasmic extract of HeLa cells, in contrast to the largely nuclear BLM and WRN helicases. However, in untransformed WI-38 fibroblasts, RECQL4 was found to be largely nuclear, and was present at significantly lower total levels than in transformed HeLa cells. RECQL4 from HeLa cells was isolated as a stable complex with UBR1 and UBR2. These 200 kDa proteins are ubiquitin ligases of the N-end rule pathway, whose substrates include proteins with destabilizing N-terminal residues. The functions of this proteolytic pathway include the regulation of peptide import, chromosome stability, meiosis, apoptosis and cardiovascular development. Although the known role of UBR1 and UBR2 is to mediate polyubiquitylation (and subsequent degradation) of their substrates, the UBR1/2-bound RECQL4 was not ubiquitylated in vivo, and was a long-lived protein in HeLa cells. The isolated RECQL4–UBR1/2 complex had a DNA-stimulated ATPase activity, but was inactive in DNA-based assays for helicases and translocases, the assays in which the BLM helicase was active. We discuss ramifications of these results, possible functions of RECQL4, and the involvement of the N-end rule pathway.
Additional Information
© 2004 Oxford University Press. Received May 6, 2004; Revised and Accepted August 11, 2004. First published online: August 18, 2004. We thank Jee Young An for carrying out DNA transfection tests with AG05013 cells, and the National Cell Culture Center for providing HeLa cells. This work was supported, in part, by the grants to W.W. from the Ellison Medical Foundation, the Rett Syndrome Research Foundation, and the Fanconi Anemia Research Foundation, by the NIH Grant GM31530 and the Max Planck Research Award (Germany) to A.V. and by the NIH Grant GM69482 to Y.T.K.Additional details
- Eprint ID
- 25852
- Resolver ID
- CaltechAUTHORS:20111004-142209812
- Ellison Medical Foundation
- Rett Syndrome Research Foundation
- Fanconi Anemia Research Foundation
- NIH
- GM31530
- Max Planck Society
- NIH
- GM69482
- Created
-
2011-10-05Created from EPrint's datestamp field
- Updated
-
2021-11-09Created from EPrint's last_modified field